FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:669-681 August 30, 2001 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

Gastroesophageal variceal hemorrhage, a major complication of portal hypertension resulting from cirrhosis, accounts for 10 to 30 percent of all cases of bleeding from the upper gastrointestinal tract.¹ Variceal hemorrhage occurs in 25 to 35 percent of patients with cirrhosis and accounts for 80 to 90 percent of bleeding episodes in these patients.^2,3,4 Variceal hemorrhage is associated with more substantial morbidity and mortality than other causes of gastrointestinal bleeding, as well as with higher hospital costs.^5,6,7 Up to 30 percent of initial bleeding episodes are fatal, and as many as 70 percent of survivors have recurrent bleeding after a first . . . [Full Text of this Article]

Pathogenesis of Gastroesophageal Varices

Prediction of Variceal Hemorrhage

Primary Prevention of Bleeding from Esophageal Varices

Pharmacologic Therapy

Endoscopic Therapy

Management of Acute Variceal Hemorrhage

Pharmacologic Therapy

Endoscopic Therapy

Balloon Tamponade

Transjugular Intrahepatic Portosystemic Shunt

Surgical Therapy

Prevention of Recurrent Variceal Bleeding

Pharmacologic Therapy

Endoscopic Therapy

Transjugular Intrahepatic Portosystemic Shunt

Surgical Therapy

Cost Effectiveness of Available Therapies

Conclusions

Source Information

From the Division of Gastroenterology, Department of Medicine, American University of Beirut Medical Center, Beirut, Lebanon (A.I.S.); and the Division of Gastroenterology, Department of Medicine, and the Duke Liver Center, Duke University Medical Center, Durham, N.C. (A.I.S., D.C.R.).

Address reprint requests to Dr. Rockey at the Duke Liver Center, DUMC Box 3083, Duke University Medical Center, Durham, NC 27710, or at dcrockey@acpub.duke.edu.

References

This article has been cited by other articles:

• Tariq, M, Jafri, W, Ansari, T, Awan, S, Ali, F, Shah, M, Jamil, S, Riaz, M, Shafqat, S (2009). Medical mortality in Pakistan: experience at a tertiary care hospital. Postgrad. Med. J. 85: 470-474 [Abstract] [Full Text]  
• Gonzalez, R., Zamora, J., Gomez-Camarero, J., Molinero, L.-M., Banares, R., Albillos, A. (2008). Meta-analysis: Combination Endoscopic and Drug Therapy to Prevent Variceal Rebleeding in Cirrhosis. ANN INTERN MED 149: 109-122 [Abstract] [Full Text]  
• O'Beirne, J. P., Foxton, M. R., Heneghan, M. A., Bhaskar, M. E., Gines, P., Cardenas, A., Arroyo, V. (2004). Management of Cirrhosis and Ascites. NEJM 351: 300-301 [Full Text]  
• Cooper, J. D., Lefrak, S. S., Meyers, F. J., Dillard, L. S., Mintz, J., Fishman, A., Naunheim, K., Piantadosi, S., Drazen, J. M. (2002). Surgery for Emphysema. NEJM 346: 860-862 [Full Text]  
• Novick, D. M., Villanueva, C., Minana, J., Balanzo, J. (2002). Prevention of Recurrent Variceal Bleeding. NEJM 346: 209-210 [Full Text]